JAROD
-
USFDA issues warning letter to Zydus Lifesciences for injectables unit at Jarod
The warning letter issued by the US Food and Drug Administration (USFDA) relating to its injectables manufacturing facility at Jarod does not contain any data integrity-related violations, Zydus Lifesciences said in a regulatory filing.
-
Zydus scrip slips nearly 3% on USFDA observations
-
Zydus receives USFDA’s final approval for Ephedrine Sulfate Injection
-
Zydus Lifesciences gets USFDA nod to market generic drug
-
USFDA issues 3 observations on Zydus' Jarod manufacturing unit
-
USFDA issues 3 observations on Zydus' Jarod manufacturing unit
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
